4//SEC Filing
TRANSKARYOTIC THERAPIES INC 4
Accession 0001104659-05-035137
CIK 0000885259operating
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 4:43 PM ET
Size
16.0 KB
Accession
0001104659-05-035137
Insider Transaction Report
Form 4
Kirby Neil
Sr. VP- Strategic Prod. Dev.
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2005-07-27$15.26/sh−40,000$610,400→ 0 totalExercise: $21.74Exp: 2014-11-11→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2005-07-27$13.21/sh−15,000$198,150→ 0 totalExercise: $23.79Exp: 2015-03-24→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2005-07-27$27.24/sh−4,500$122,580→ 0 totalExercise: $9.76Exp: 2013-06-11→ Common Stock (4,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2005-07-27$31.16/sh−18,000$560,880→ 0 totalExercise: $5.84Exp: 2013-03-28→ Common Stock (18,000 underlying)
Footnotes (5)
- [F1]This option, which was granted on March 24, 2005 and provided for vesting in three equal installments beginning on March 24, 2006, was cancelled pursuant to a merger agreement among the Issuer, Shire Pharmaceuticals Group plc and Sparta Acquisition Corporation, dated April 21, 2005, in exchange for a cash payment of $198,150, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F2]This option, which was granted on November 11, 2004 and provided for vesting in three approximately equal annual installments beginning on November 11, 2005, was cancelled in the merger in exchange for a cash payment of $610,400, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F3]This option, which was granted on March 24, 2004 and provided for vesting in three equal annual installments beginning on March 24, 2005, was cancelled in the merger in exchange for a cash payment of $395,700, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F4]This option, which was granted on June 11, 2003 and provided for vesting in four equal semi-annual installments beginning on December 11, 2003, was cancelled in the merger in exchange for a cash payment of $122,580, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
- [F5]This option, which was granted on March 28, 2003 and provided for vesting in four equal semi-annual installments beginning on September 28, 2003, was cancelled in the merger in exchange for a cash payment of $560,880, representing the excess of $37.00 over the per share exercise price of the option multiplied by the number of shares subject to the option, whether vested or unvested.
Documents
Issuer
TRANSKARYOTIC THERAPIES INC
CIK 0000885259
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000885259
Filing Metadata
- Form type
- 4
- Filed
- Jul 28, 8:00 PM ET
- Accepted
- Jul 29, 4:43 PM ET
- Size
- 16.0 KB